Thyme Care

A while back I interviewed the Thyme Care team about the future of value-based oncology care, and I'm finally getting around to posting it on Hospitalogy. Here was an excellent excerpt from Bobby Green and Scott Voigt I enjoyed: When it comes to value-based models, cancer care today is where chronic kidney care was five or more years ago. And, just as success with chronic kidney patients relies on a kidney-focused care model that is integrated with the nephrologist, cancer care can be greatly enhanced by deploying oncology-focused clinical navigation in partnership with oncologists. For investors, there is significant upside in investing in value-based care enablers (like Strive Health in kidney care, Thyme Care in cancer care). As the healthcare industry continues to shift from FFS to VBC, we will see more niches follow suit after primary care, kidney care and cancer. For providers, it’s very difficult for them to address the multi-faceted needs of their patients while keeping pace with the number of patients they have to see, especially as the supply of specialists continues to be under pressure. They should consider value-based partners to help make that kind of support possible while reducing the need for avoidable and costly acute care services. Value-based care transformation in cancer requires more than just aligned financial incentives, it requires a deep understanding of where the opportunities for enhancement and cost-savings lie, an emphasis on reduction of acute care utilization, and an appreciation for novel solutions such as patient navigation that payers and practices may find difficult to fund and build in-house.